Zevra Therapeutics (ZVRA) Change in Accured Expenses (2014 - 2026)
Zevra Therapeutics (ZVRA) posted Change in Accured Expenses of -$529000.0 for Q1 2026, down 228.4% on a QoQ basis from $412000.0 in Q4 2025, and up 92.72% year-over-year from -$274493.6 in Q1 2025.
Zevra Therapeutics (ZVRA) Change in Accured Expenses (2014 - 2026) Analysis & Trends
Zevra Therapeutics' Change in Accured Expenses history runs 13 years deep, the most recent figure standing at -$529000.0 for Q1 2026.
- Quarterly Change in Accured Expenses rose 92.72% year-over-year to -$529000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.9 million (down 148.83% YoY) and the FY2025 annual result came in at -$15.6 million, down 333.21% from the prior year.
- Change in Accured Expenses was -$529000.0 for Q1 2026 at Zevra Therapeutics, down from $412000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $7.0 million in Q4 2024 and bottomed at -$7.3 million in Q1 2024.
- A 5-year average of -$320764.7 and a median of -$486000.0 in 2022 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 889.3% — and 2024, when it plunged 290.46%.
- Zevra Therapeutics' Change in Accured Expenses stood at $1.9 million in 2022, then jumped by 206.58% to $5.7 million in 2023, then climbed by 22.02% to $7.0 million in 2024, then plunged by 94.11% to $412000.0 in 2025, then slumped by 228.4% to -$529000.0 in 2026.
- Business Quant data shows ZVRA's Change in Accured Expenses at -$529000.0 in Q1 2026, $412000.0 in Q4 2025, and -$4.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 470.97 Bn | 466.18 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.05 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.42 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Zevra Therapeutics | 566.54 Mn | 365.92 Mn | 34.32 Mn | -529,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -529,000.00 |
| Mar 31, 2026 | -529,000.00 |
| Dec 31, 2025 | 412,000.00 |
| Dec 31, 2025 | 412,000.00 |
| Sep 30, 2025 | -4.73 Mn |
| Sep 30, 2025 | -4.73 Mn |
| Jun 30, 2025 | -4.00 Mn |
| Jun 30, 2025 | -4.00 Mn |
| Mar 31, 2025 | -7.27 Mn |
| Mar 31, 2025 | -7.27 Mn |
| Dec 31, 2024 | 6.99 Mn |
| Dec 31, 2024 | 6.99 Mn |
| Sep 30, 2024 | -1.99 Mn |
| Sep 30, 2024 | -1.99 Mn |
| Jun 30, 2024 | -1.30 Mn |
| Jun 30, 2024 | -1.30 Mn |
| Mar 31, 2024 | -7.31 Mn |
| Mar 31, 2024 | -7.31 Mn |
| Dec 31, 2023 | 5.73 Mn |
| Dec 31, 2023 | 5.73 Mn |